BioSpace News Archive

JOGO Health, a value-based virtual care company that leverages proprietary digital interventions to provide comprehensive rehabilitation for chronic pain and neuromuscular conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its chronic lower back pain product, JOGO-CLBP.

Viscient Bio, Inc. (“Viscient”) today announced it has identified the world’s first drug candidate discovered primarily using 3D bioprinted tissue models of disease formed from human cells.

RaySearch Laboraties AB announces that Yonsei Cancer Center in South Korea has treated its first patient using RayStation®* and RayCare®* for carbon ion radiation therapy.

3M announced it has entered into agreements to sell certain assets associated with its dental local anesthetic portfolio, based in Seefeld, Germany, to Pierrel S.p.A., a global provider of services for the pharmaceutical industry, for a purchase price of $70 million, subject to closing and other adjustments.

Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces a Key Opinion Leader (KOL) event will be hosted by Ladenburg Thalmann & Co, Inc., on Tuesday, May 9, 2023, from 11:30 AM – 1:00 PM ET.

Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Tuesday, May 9, 2023, at 4:30 p.m. Eastern Time to report financial results for the first quarter 2023 and to highlight recent corporate progress.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) today announced the enrollment of the last subject in the INTEGUMENT-PED Pivotal Phase 3 trial evaluating roflumilast cream 0.05% for the treatment of mild to moderate AD in children ages 2 to 5.

AbbVie (NYSE: ABBV) will participate in the Bank of America Securities Healthcare Conference on Tuesday, May 9, 2023.

Amyris, Inc. today announced that it will issue its financial results for the first quarter ended March 31, 2023, on the afternoon of Tuesday, May 9, 2023, after closing of the financial markets

The U.S. market for medicines grew by 5% in 2022, reaching a total value of $429Bn on a net price basis.